Form 4: Akero Therapeutics Director Increases Direct Stock Ownership Through Restricted Stock Unit Grant

Akero Therapeutics, Inc. Director Graham G. Walmsley reported the acquisition of 9,398 restricted stock units, increasing his direct beneficial ownership in the company.

Summary

• Graham G. Walmsley, a Director of Akero Therapeutics, Inc. (AKRO), reported a transaction on June 3, 2025.
• He acquired 9,398 shares of Common Stock in the form of restricted stock units (RSUs) at a price of $0.
• These RSUs are contingent rights to receive one share of Common Stock each and will vest in full on the earlier of June 3, 2026, or the next annual meeting of the Company's stockholders, subject to his continued service on the Board.
• Following this transaction, Mr. Walmsley directly beneficially owns 11,566 shares of Common Stock.
• Additionally, he indirectly beneficially owns 1,200,000 shares held by Logos Global Master Fund LP and Logos Opportunities Fund IV LP, where he is a managing member of their respective general partners, Logos GP LLC and Logos Opportunities IV GP LLC. He disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the transaction represents an increase in direct beneficial ownership by a director, aligning their interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event rather than a significant strategic move.

Positives

• The acquisition of restricted stock units by a director indicates continued alignment of management's interests with those of shareholders, as the value of these units is tied to the company's stock performance.

Future Outlook

The acquired restricted stock units are set to vest on the earlier of June 3, 2026, or the next annual meeting of the Company's stockholders, contingent on the director's continued service.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common in publicly traded companies as part of executive and director compensation packages, and does not directly reflect broader industry trends.

Related Party Transactions

• The reporting person indirectly holds 1,200,000 shares through Logos Global Master Fund LP and Logos Opportunities Fund IV LP, where he serves as a managing member of their respective general partners. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The increase in direct beneficial ownership by a director through an RSU grant can be seen as a positive signal, as it further aligns the director's financial interests with the long-term performance of the company's stock, potentially benefiting shareholders.

Next Steps

• The restricted stock units are expected to vest on the earlier of June 3, 2026, or the next annual meeting of the Company's stockholders, subject to continued service.

Key Dates

Keywords

Akero Therapeutics, AKRO, Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, RSU, Director Stock Ownership, Corporate Governance